TrialJournal for immunotherapy of cancer2024

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.

Brian S Henick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.